2016
DOI: 10.1016/j.jns.2016.06.034
|View full text |Cite
|
Sign up to set email alerts
|

Multifocal inflammatory demyelination in a patient with rheumatoid arthritis and treatment complications

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
1
0

Year Published

2016
2016
2021
2021

Publication Types

Select...
2

Relationship

1
1

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 10 publications
0
1
0
Order By: Relevance
“…complicated but typically accompanied by the CNS and/or systemic infiltration of T-cells (particularly CD8+ T-cells) that supposedly fight against the development of toxoplasmosis[72][73][74][75]. While untreated patients with autoimmune diseases typically have more infiltrating Tcells, immunosuppressant and/or immunomodulatory treatment of autoimmune diseases (such as medication for RA and hematopoietic stem cell transplantation for MS) may reduce but not completely deplete the infiltration of T-cells particularly in the CNS[74,76]. The potentially persistent presence of infiltrating T-cells in the CNS should prevent the development of CNS toxoplasmosis in those patients with autoimmune diseases even following successful immunosuppressant and/or immunomodulatory treatment.…”
mentioning
confidence: 99%
“…complicated but typically accompanied by the CNS and/or systemic infiltration of T-cells (particularly CD8+ T-cells) that supposedly fight against the development of toxoplasmosis[72][73][74][75]. While untreated patients with autoimmune diseases typically have more infiltrating Tcells, immunosuppressant and/or immunomodulatory treatment of autoimmune diseases (such as medication for RA and hematopoietic stem cell transplantation for MS) may reduce but not completely deplete the infiltration of T-cells particularly in the CNS[74,76]. The potentially persistent presence of infiltrating T-cells in the CNS should prevent the development of CNS toxoplasmosis in those patients with autoimmune diseases even following successful immunosuppressant and/or immunomodulatory treatment.…”
mentioning
confidence: 99%